Nifedipine Dosing for Raynaud's Phenomenon
For adults with Raynaud's phenomenon and no contraindications, start with extended-release nifedipine 30 mg once daily orally, and titrate up to 60-90 mg daily based on therapeutic response and tolerability.
Recommended Dosing Strategy
The 2025 EULAR guidelines for systemic sclerosis explicitly recommend dihydropyridine-type calcium antagonists, usually oral nifedipine, as first-line therapy for Raynaud's phenomenon 1. This represents the highest quality, most recent guideline evidence specific to Raynaud's.
Starting Dose and Titration
- Initial dose: 30 mg once daily (extended-release formulation)
- Titration period: 7-14 days between dose adjustments
- Maintenance dose: 30-60 mg once daily (most common effective range)
- Maximum dose: 90 mg once daily (doses above 90 mg are not recommended)
The FDA-approved dosing for extended-release nifedipine specifies this exact titration schedule 2. Tablets must be swallowed whole on an empty stomach—never crushed, chewed, or divided 2.
Formulation Matters Critically
Use only extended-release (slow-release) formulations for Raynaud's. Multiple ACC/AHA guidelines explicitly warn that immediate-release nifedipine poses increased adverse potential and should be avoided except with concomitant beta blockade 3, 4, 3. The immediate-release formulation causes unpredictable blood pressure responses and reflex tachycardia that can precipitate cardiovascular events 5.
The extended-release formulation provides:
- Steady plasma levels with peak at 2.5-5 hours
- Elimination half-life of ~7 hours (vs. 2 hours for immediate-release)
- Reduced fluctuations in blood pressure
- Better tolerability profile
Clinical Evidence Supporting This Dosing
Research demonstrates dose-dependent efficacy:
- 20 mg twice daily (40 mg total): Reduced attack frequency by 40% in primary Raynaud's 6
- 20 mg twice daily: Improved symptoms, reduced attack frequency and duration, with objective plethysmographic improvements 7
- 20 mg twice daily: 25% reduction in mean attacks with acceptable tolerability 8
- Dose titration studies: Individual optimization ranged from 20-80 mg daily based on therapeutic effect and side effects, with sustained long-term efficacy 7
The evidence supports starting at 30 mg daily and titrating to 60-90 mg as the therapeutic sweet spot for most patients.
Important Safety Considerations
Common Side Effects (Dose-Related)
- Hypotension, dizziness, flushing
- Peripheral edema
- Headache
- Nausea, constipation
Side effects are more common and persistent at higher doses 6. If hypotension becomes problematic, consider:
- Topical nifedipine 10% cream as adjunctive therapy (comparable efficacy to oral with fewer systemic effects) 9
- Alternative agents like losartan or sildenafil if hypotension is severe 9, 10
Critical Drug Interactions
Avoid grapefruit juice entirely—it increases nifedipine bioavailability by ~60% and prolongs time to peak concentration 2.
Administration Timing
Take on an empty stomach. High-fat meals increase peak plasma concentration by 60% and prolong absorption, creating unpredictable effects 2.
When to Consider Alternatives
If nifedipine at 60-90 mg daily fails to control symptoms or causes intolerable side effects:
- PDE5 inhibitors (e.g., sildenafil) should be considered as second-line 1
- Intravenous iloprost for severe Raynaud's following oral therapy failure 1
Practical Algorithm
- Start: Extended-release nifedipine 30 mg once daily on empty stomach
- Assess at 7-14 days: Symptom improvement vs. side effects
- If inadequate response: Increase to 60 mg once daily
- Reassess at 7-14 days: Most patients achieve adequate control at 60 mg
- If still inadequate: May increase to 90 mg once daily (maximum dose)
- If intolerable side effects or hypotension: Consider dose reduction, topical formulation, or alternative agent
Never use three 30 mg tablets to achieve 90 mg dosing—this produces substantially higher peak concentrations than a single 90 mg tablet and increases adverse effects 2.